Abstract： Objective To analyze the relationship between the survival and expressions of EGFR and Her-2, and explore the prognostic significance of EGFR and Her-2 in gastric cancer patient by detecting the expressions of EGFR and Her-2 in gastric cancer specimens. Methods EGFR and Her-2 were detected by immunohistochemistry. The relation between their expressions with their clinical characteristics and prognosis were analyzed. Results The over-expression rates of EGFR and Her-2 are 27.4 % and 32.1% respectively in 84 cases. The over-expression rates of EGFR and Her-2 in patients with Ⅲ + Ⅳ stages were significantly higher than those with Ⅰ + Ⅱ stages(respectively, P =0.014 and P =0.005). The positive rate in patients with T3+T4 stages were significantly higher than those with T1+T2 stages (P=0.033); and the positive rate in patients with positive lymph node was higher significantly than that with negative (P =0.033). The OS and PFS in over-expression patients were significantly longer than low-expression. Conclusion The overexpression of EGFR and Her-2 could be used to evaluate the degree of differentiation and prognosis of patients with gastric cancer.